Bone health
Report
Mar. 16, 2010•0 likes•847 views
2 likes
Be the first to like this
Show More
views
Total views
0
On Slideshare
0
From embeds
0
Number of embeds
0
Check these out next
Bone health
Mar. 16, 2010•0 likes•847 views
2 likes
Be the first to like this
Show More
views
Total views
0
On Slideshare
0
From embeds
0
Number of embeds
0
Report
Health & Medicine
Entertainment & Humor
How to prevent osteoporosis, fracture on simple fall.
Bone health
- Dr Ling Sien Ngan Anti Aging, Aesthetic Medical Practitioner
- Bone Health Dr Ling Sien Ngan Anti Aging, Aesthetic Medical Practitioner
- Lowel Anti Aging + Aesthetic Center , SS2 ,PJ
- Anti Aging & Aesthetic medical practitioner 1. Anti Aging medicine 2. Men’s health & Andrology 5. Cosmetic surgery 4. Cosmetic Dermatology 3. Holistic complimentary medicine Aesthetic / External Anti aging
- vs Wellness Industry Sickness Industry Anti Aging Medicine is Even here can still anti age !
- + - - - + + - Somatostatin - GHRH GHRP GHRELIN HGH + IGF-1 + + Muscle, Bone, Cartilage FAT + + THYMUS BRAIN GONAD LIVER + - - Hypothalamus Anterior Pituitary + STOMACH
- Bone remodeling = dynamic , continuous Bone Resorption Formation Ca lost from bone Through kidney Ca absorbed from blood Blood vessel Urine Gut
- Osteoclast eat up bone
- Osteoblast form bone structure
- ACLASTA Annual dosing: A new paradigm in the treatment of osteoporosis 1 infusion , year long protection
- Zoledronic reduced risk of fractures N America/ Oceania 64%* (23%, 83%) Western Europe 73%† (58%, 83%) 2.4% 6.5% 2.8% 10.6% Latin America 54%† (23%, 72%) 3.7% 8.4% % Patients With New Vertebral Fracture 0 10 5 15 Asia 3.0% Eastern Europe 4.2% 15% 13% 80%† (65%, 89%) 68%† (51%, 79%) ZOL 5 mg Placebo
- Mean Serum β -CTX Over Time Beta crossLab Mean (± SE) Serum β -CTX (ng/mL) 0.3 0.2 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Weeks 0.0 0.5 0.4 0.1 * ‡ * * * * ZOL 5 mg (n = 69) ALN 70 mg (n = 59)
Editor's Notes
- HORIZON-PFT Study 2301 Slide Library V3 1-May-07 CONFIDENTIAL HORIZON-PFT Slide Library - Osteoporosis: Summary The hallmark of osteoporosis is microarchitectural degeneration of bone tissue 1,2 The rate of bone resorption exceeds the rate of bone formation in older adults, particularly in postmenopausal women Osteoporosis results from this imbalance between bone resorption and formation Bone mass is lost, density is reduced, and bones become fragile, thin and brittle In the year 2000, there were an estimated 9.0 million osteoporotic fractures of which 1.4 million were clinical vertebral fractures, 1.6 million were at the hip, and 1.7 million at the forearm 3 The majority of these osteoporotic fractures occurred in Europe (34.8% of the total) 4 Osteoporosis is a major public health threat with serious clinical consequences. The disease places a significant burden on society in terms of public health, healthcare resources, direct medical costs such as surgical procedures, and indirect medical costs such as lost productivity 5–8 Of the many available treatments for osteoporosis, bisphosphonates are the choice for first-line therapy in most countries worldwide References Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med . 1998;338:737–746. Follin SL, Hansen LB. Current approaches to the prevention and treatment of postmenopausal osteoporosis. Am J Health Syst Pharm . 2003;60:883–901. Inter national Osteoporosis Foundation (IOF). Available at: http://www.iofbonehealth.org/iof-articles/article-detail.html?articleID=27. Accessed 21 May 2008. International Osteoporosis Foundation (IOF). Available at: http://www.iofbonehealth.org/policy-advocacy/europe.html. Accessed 21 May 2008. National Osteoporosis Foundation. Fast Facts on Osteoporosis. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed 23 May 2008. International Osteoporosis Foundation (IOF). Available at: http://www.iofbonehealth.org/facts-and-statistics.html. Accessed 23 May 2008. Delmas PD, van de Langerijt L, Watts NB, for the IMPACT Study Group. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res . 2005;20:557–563. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res . 2007;22:465–475.
- Richard v W, Achala & Jaime from Singapore Fellow colleagues from NVR M’sia Appreciate your presents to review the LRR together (Aik Hwa- to do the introduction)
- Zoledronic Acid Reduced 3-Year Risk of Vertebral Fractures (by Geographic Region) ZOL 5 mg produced significant reductions in vertebral fracture risk in patients in all geographic regions studied (54% to 84% reduction). Because there were a small number of events and confidence intervals wide one can not draw conclusions about the staistical significance, however, the general trends reflect the primary efficacy results. Within-subgroup P-values are based on logistic regression with treatment, baseline fracture status in the model using log-likelihood type approach. Reference Cauley J, Black D, Boonen S, et al. Effect of zoledronic acid (ZOL) 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: results from HORIZON-PFT [abstract]. Osteoporos Int . 2007;18(suppl 1):S26. Abstract OC53.
- Mean Serum β-CTX Over Time Reductions in serum β-CTX levels over time were similar to those observed for urine NTX, with zoledronic acid resulting in significantly greater reductions in serum β-CTX levels at all postbaseline time points compared with alendronate. At Week 24, mean β-CTX was within the premenopausal reference range (0.117 – 0.606 ng/mL [Synarc, Lyon, France]) in the alendronate group and slightly below the reference range in the zoledronic acid group (mean 0.114, SE = 0.011). Reference Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone . 2007;40:1238-1243.
- HORIZON-PFT Study 2301 Slide Library V3 1-May-07 CONFIDENTIAL HORIZON-PFT Slide Library -
- Summary Switching patients who had been treated with oral alendronate 70 mg for an average of 4 years to a single dose of IV zoledronic acid 5 mg resulted in persistence of the inhibition of bone remodeling and stability of BMD in a very similar range as if they had remained on alendronate therapy. The switch from oral to IV therapy was well tolerated, and the overall frequency of AEs was comparable in both groups. The majority of patients in both treatment groups expressed preference for once yearly infusion over weekly oral therapy. An annual infusion would ensure adherence for a full 12 months, and the maintenance of BMD seen 12 months after a single infusion of zoledronic acid 5 mg supports its use in women who have previously been treated with oral alendronate. Reference McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone . 2007;41:122-128.